[go: up one dir, main page]

ATE446953T1 - P2X7 RECEPTOR ANTAGONISTS AND THEIR USE - Google Patents

P2X7 RECEPTOR ANTAGONISTS AND THEIR USE

Info

Publication number
ATE446953T1
ATE446953T1 AT04735697T AT04735697T ATE446953T1 AT E446953 T1 ATE446953 T1 AT E446953T1 AT 04735697 T AT04735697 T AT 04735697T AT 04735697 T AT04735697 T AT 04735697T AT E446953 T1 ATE446953 T1 AT E446953T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT04735697T
Other languages
German (de)
Inventor
Richard Evans
Christine Eyssade
Rhonan Ford
Barrie Martin
Toby Thompson
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446953(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE446953T1 publication Critical patent/ATE446953T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04735697T 2003-06-02 2004-06-01 P2X7 RECEPTOR ANTAGONISTS AND THEIR USE ATE446953T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (en) 2003-06-02 2003-06-10 Novel compounds
PCT/SE2004/000836 WO2004106305A1 (en) 2003-06-02 2004-06-01 New p2x7 receptor antagonists and their use

Publications (1)

Publication Number Publication Date
ATE446953T1 true ATE446953T1 (en) 2009-11-15

Family

ID=38812906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735697T ATE446953T1 (en) 2003-06-02 2004-06-01 P2X7 RECEPTOR ANTAGONISTS AND THEIR USE

Country Status (25)

Country Link
US (2) US7408065B2 (en)
EP (1) EP1633717B1 (en)
JP (1) JP4682128B2 (en)
KR (1) KR101244971B1 (en)
CN (1) CN1832925B (en)
AR (1) AR045691A1 (en)
AT (1) ATE446953T1 (en)
AU (1) AU2004242626B2 (en)
BR (1) BRPI0410933A (en)
CA (1) CA2526884C (en)
CO (1) CO5700720A2 (en)
DE (1) DE602004023840D1 (en)
ES (1) ES2333721T3 (en)
GB (1) GB0312609D0 (en)
IS (1) IS8190A (en)
MX (1) MXPA05012883A (en)
NO (1) NO20060001L (en)
RU (1) RU2347778C2 (en)
SA (1) SA04250155B1 (en)
SE (1) SE0301700D0 (en)
TW (1) TW200508214A (en)
UA (1) UA83659C2 (en)
UY (1) UY28342A1 (en)
WO (1) WO2004106305A1 (en)
ZA (1) ZA200509706B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2006032851A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
JP2008526840A (en) * 2005-01-06 2008-07-24 アストラゼネカ アクチボラグ New compounds
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US20080312208A1 (en) * 2005-07-13 2008-12-18 Astrazeneca Ab Pyridine Analogues
CN101232890A (en) * 2005-08-01 2008-07-30 芬诺密克斯公司 Methods of preparing heterocyclic boronic acids and derivatives thereof
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2006310367A1 (en) * 2005-10-31 2007-05-10 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (en) * 2005-11-01 2009-04-02 バイオリポックス エービー Pyrazole compounds useful for the treatment of inflammation
US8007849B2 (en) 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
ES2569677T3 (en) 2006-03-16 2016-05-12 Second Genome, Inc. Bicycloheteroaryl compounds as modulators of P2X7 and uses thereof
US20090298825A1 (en) * 2006-03-16 2009-12-03 Kelly Michael G Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
EP1937643B1 (en) * 2006-03-16 2016-07-13 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20080058309A1 (en) * 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
MX2009003170A (en) * 2006-09-28 2009-04-03 Hoffmann La Roche Quinoline derivatives with 5-ht-binding properties.
ZA200904477B (en) 2006-11-27 2010-09-29 Lundbeck & Co As H Heteroaryl amide derivatives
WO2008068157A1 (en) * 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht(5a) receptor antagonists
CA2680761A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
EP2592082A1 (en) * 2007-04-10 2013-05-15 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
PE20091036A1 (en) * 2007-11-30 2009-08-15 Astrazeneca Ab QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
CA2715842A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoline derivatives
ATE494926T1 (en) 2008-03-25 2011-01-15 Affectis Pharmaceuticals Ag NOVEL P2X7R ANTAGONISTS AND THEIR USE
AU2009239471B2 (en) * 2008-04-22 2013-01-24 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
ES2380908T3 (en) 2009-04-14 2012-05-21 Affectis Pharmaceuticals Ag Novelty p2x7r antagonists and their use
CA2761639C (en) * 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (en) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 As P2X7The heterocyclic amide derivative of receptor antagonist
CN104066737B (en) 2012-01-20 2016-06-08 埃科特莱茵药品有限公司 As P2X7The heterocyclic amide derivative of receptor antagonist
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
JP6282016B2 (en) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Heterocyclic amide derivatives as P2X7 receptor antagonists
ES2616883T3 (en) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3773B1 (en) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv P2X7 rates
JO3509B1 (en) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv P2x7 modulators
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
AR100724A1 (en) * 2014-06-05 2016-10-26 Merck Patent Gmbh DERIVATIVES OF QUINOLINA AND ITS USE IN NEURODEGENERATIVE DISEASES
US20180118749A1 (en) 2014-09-12 2018-05-03 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315687B2 (en) 2014-09-12 2019-07-11 Janssen Pharmaceutica Nv P2X7 modulators
CN106084068B (en) * 2016-06-16 2019-07-16 郑州大学第一附属医院 A Group of Enterobactin-Antibiotic Derivatives and Their Applications
RS64995B1 (en) * 2017-03-13 2024-01-31 Raqualia Pharma Inc Tetrahydroquinoline derivatives as p2x7 receptor antagonists
EP3398941A1 (en) * 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
JOP20210058A1 (en) 2018-09-28 2021-03-24 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20220075386A (en) 2019-09-30 2022-06-08 얀센 파마슈티카 엔.브이. Radiolabeled MGL PET Ligand
EP4126860A1 (en) 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
CN115305282A (en) * 2022-08-04 2022-11-08 烟台毓璜顶医院 A target and treatment method for AR-induced OD diagnosis and prognosis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US3741491A (en) * 1971-11-29 1973-06-26 Leesona Corp Apparatus for winding yarn
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
EP0501656B1 (en) 1991-02-21 1997-01-22 Sankyo Company Limited New benzene derivatives having (NGF) production-promoting activity
SG52229A1 (en) 1993-08-10 1998-09-28 Black James Foundation Gastrin and cck receptor ligands
KR100316571B1 (en) 1994-05-27 2002-05-30 파올로 비지, 엔리꼬 카쭐라니 Quinoline derivatives as tachykinin NK3 receptor antagonists
AR004735A1 (en) 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
SK283162B6 (en) * 1996-05-20 2003-03-04 Darwin Discovery Limited Quinoline carboxamides as TNF inhibitors and PDE-IV inhibitors
FR2761358B1 (en) 1997-03-27 1999-05-07 Adir NOVEL N-ARYL PIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
SE9704544D0 (en) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (en) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (en) 1999-04-09 2002-05-15 Astrazeneca Ab Adamantane derivatives
CN1789246A (en) 1999-06-02 2006-06-21 Nps药物有限公司 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
MXPA02004985A (en) * 1999-11-26 2003-10-14 Shionogi & Co Npyy5 antagonists.
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
CN1261099C (en) * 2001-07-02 2006-06-28 阿克佐诺贝尔公司 Tetrahydroquinoline derivatives
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (en) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
JP2005519876A (en) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド 2-aminoquinoline compounds
SE0200920D0 (en) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (en) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (en) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
BRPI0410933A (en) 2006-06-27
KR20060015741A (en) 2006-02-20
GB0312609D0 (en) 2003-07-09
CN1832925A (en) 2006-09-13
HK1085736A1 (en) 2006-09-01
AR045691A1 (en) 2005-11-09
SA04250155B1 (en) 2008-11-15
KR101244971B1 (en) 2013-03-18
RU2005136130A (en) 2006-06-27
TW200508214A (en) 2005-03-01
JP2006526617A (en) 2006-11-24
CA2526884A1 (en) 2004-12-09
US7408065B2 (en) 2008-08-05
AU2004242626A1 (en) 2004-12-09
ZA200509706B (en) 2006-12-27
DE602004023840D1 (en) 2009-12-10
ES2333721T3 (en) 2010-02-26
AU2004242626B2 (en) 2008-03-13
RU2347778C2 (en) 2009-02-27
SE0301700D0 (en) 2003-06-10
EP1633717A1 (en) 2006-03-15
IS8190A (en) 2005-12-21
US20090143354A1 (en) 2009-06-04
WO2004106305A1 (en) 2004-12-09
CN1832925B (en) 2010-05-05
EP1633717B1 (en) 2009-10-28
JP4682128B2 (en) 2011-05-11
UA83659C2 (en) 2008-08-11
CA2526884C (en) 2012-10-16
CO5700720A2 (en) 2006-11-30
MXPA05012883A (en) 2006-02-22
NO20060001L (en) 2006-03-02
US20060293337A1 (en) 2006-12-28
UY28342A1 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
ATE446953T1 (en) P2X7 RECEPTOR ANTAGONISTS AND THEIR USE
DE602005023639D1 (en) CHINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARIN M3 RECEPTOR ANTAGONISTS
DE60112322D1 (en) AMINOTHIAZOLE AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS
ATE378338T1 (en) PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS
ATE435872T1 (en) ANTI-INTERLEUKIN-1 RECEPTOR ANTIBODIES AND THEIR USE
DE602004025332D1 (en) ANTIBODY TO IL21 RECEPTOR AND ITS USE
DE602004021904D1 (en) GYRASEINHIBITORS AND THEIR USES
DE602004031988D1 (en) Antibodies against insulin-like growth factor I receptor and their use
ATE381335T1 (en) 2-CYANOPYRROLOPYRIMIDINES AND THEIR PHARMACEUTICAL USE
ATE414690T1 (en) FLUORO-SUBSTITUTED CYCLOALKANINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
DE60113719D1 (en) CHINUCLIDINCARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS
DE60114413D1 (en) SUBSTITUTED 1-AMINOALKYL-LACTAME AND THEIR USE AS MUSCARIN RECEPTOR ANTAGONISTS
ATE420659T1 (en) CRIPTO-BLOCKING ANTIBODIES AND THEIR USE
ATE409182T1 (en) TETRAHYDROCINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMA RECEPTORS
DE60336266D1 (en) SUBSTITUTED 1-PIPERIDIN-4-YL-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS
DE60325493D1 (en) SUBSTITUTED 1,4-DIPIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS
DE60106607D1 (en) SUBSTITUTED 1-AMINOALKYL-LACTAME AND THEIR USE AS MUSCARIN RECEPTOR ANTAGONISTS
EP1746902A4 (en) MULTILEKTIN AFFINICHROMATOGRAPHY AND USE THEREOF
DE602004027354D1 (en) SUBSTITUTED 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON AND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATES AND THEIR USE IN NEURODEEGENERATIVE DISEASES
EP1469860A4 (en) ANTIQUE COMBINATION AND ITS USE
DE602004022458D1 (en) PYRAZONE DERIVATIVES AND THEIR USE AS OREXINE RECEPTOR ANTAGONISTS
ATE471938T1 (en) SUBSTITUTED DIAZASPIROÄ4.5ÜDECAND DERIVATIVES AND THEIR USE AS NEUROKIN ANTAGONISTS
ATE417045T1 (en) SUBSTITUTED DIAZASPIROÄ5.5ÜUNDECANDERIVATIVES AND THEIR USE AS NEUROKIN ANTAGONISTS
DE602004028700D1 (en) Cosmetic compositions and their use
ATE396185T1 (en) SUBSTITUTED 4-ALKYL AND 4-ALKANOYLPIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKINE ANTAGONISTS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties